Emerging Trends and Growth Drivers in the Pulmonary Arterial Hypertension Market Through 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Much Is the Global Pulmonary Arterial Hypertension Market Valued at Present and by 2029?
The market size of pulmonary arterial hypertension has seen significant expansion in the past few years. The market is predicted to burgeon from $8.47 billion in 2024, reaching to $9.15 billion in 2025, with a compound annual growth rate (CAGR) of 8.0%. This upward trajectory during the past years can be credited to the heightened awareness and diagnosis of pulmonary arterial hypertension (PAH), surge in healthcare spending, the increase in the elderly population, enlargement of treatment possibilities for pulmonary arterial hypertension, and a rise in research and development activities in the field of pulmonary hypertension.
Expectations are high for significant expansion of the pulmonary arterial hypertension market in the coming years, with predictions of its growth to “$12.69 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.5%. This predicted expansion during the forecast period is largely attributed to the implementation of innovative treatments for pulmonary arterial hypertension, an intensified focus on early detection and diagnosis, an increasing pipeline of PAH drugs and therapies, the adoption of precision medicine in PAH management, and the development of healthcare infrastructure across emerging markets. Noteworthy trends for the forecast period encompass advancements in medical imaging and diagnostic technology, alliances, and partnerships for drug development, and patient-focused strategies in the management of pulmonary arterial hypertension, coupled with an uptick in the use of combination therapy.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=5954&type=smp
#What Drivers Are Influencing Growth In The Pulmonary Arterial Hypertension Market?
The pulmonary arterial hypertension market is experiencing growth due to the rising occurrence of the pulmonary arterial hypertension (PAH) disease. The escalating incidence of PAH and the associated hospital admissions for care is predicted to stimulate the need for appropriate medications throughout the projected timeline. A research released by the National Organization for Rare Disorders, Inc. suggests that in the USA, PAH is anticipated to be diagnosed in one to two persons per million annually, resulting in 500–1000 new cases each year. Comparable incident rates are anticipated in Europe as well.
What Are The Main Segments Identified In The Pulmonary Arterial Hypertension Market Research?
The pulmonary arterial hypertension market covered in this report is segmented –
1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators
2) By Route Of Administration: Oral, Intravenous Or subcutaneous, Inhalational
3) By Distribution channel: Retail, Online
Subsegments:
1) By Endothelin Receptor Antagonists (ERAs): Bosentan, Ambrisentan, Macitentan
2) By PDE-5 Inhibitors: Sildenafil, Tadalafil
3) By Prostacyclin And Prostacyclin Analogs: Epoprostenol, Treprostinil, Iloprost
4) By SGC Stimulators: Riociguat
What Upcoming Trends Are Expected To Impact The Pulmonary Arterial Hypertension Market Globally?
Major corporations in the pulmonary arterial hypertension market are pioneering sophisticated products like Winrevair to enhance the treatment possibilities and outcomes for patients grappling with this grave disease. For example, Merck & Co. Inc. – a multinational pharmaceutical firm headquartered in the US – unveiled Winrevair in March 2024 for adults suffering from pulmonary arterial hypertension. Winrevair comes as the first-ever therapy targeting activin signaling for pulmonary arterial hypertension approved by the US-based federal agency, FDA. The cutting-edge treatment functions by recalibrating the equilibrium between pro and anti-proliferative signals which govern vascular cell proliferation linked with PAH. Consequently, this ushers in an unprecedented category of therapy for this disease.
Which Companies Play A Key Role In The Development Of The Pulmonary Arterial Hypertension Market?
Major companies operating in the pulmonary arterial hypertension market include United Therapeutics Corporation, Acceleron Pharma Inc., Actelion Pharmaceuticals US Inc., Bayer AG, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Liquidia Technologies Inc., Lupin Pharmaceuticals Inc., Natco Pharma Ltd., Pfizer Inc., Sandoz AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceutical USA Inc., Allegheny Health Network, Cedars-Sinai Medical Center, Cleveland Clinic, Houston Methodist Hospital, Johns Hopkins Medicine, Massachusetts General Hospital, Mayo Clinic, MedStar Heart & Vascular Institute, National Jewish Health, NewYork-Presbyterian Hospital, Ochsner Medical Center, Royal Brompton & Harefield NHS Foundation Trust, Rush University Medical Center, Stanford Health Care, Swedish Medical Center, Temple University Hospital, University of California Health.
Get The Full Report Here:
What Are The Key Regional Developments Shaping The Pulmonary Arterial Hypertension Market?
North America was the largest region in the pulmonary arterial hypertension market in 2024. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=5954&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
